STOCK TITAN

Paragon 28 Inc Stock Price, News & Analysis

FNA NYSE

Welcome to our dedicated page for Paragon 28 news (Ticker: FNA), a resource for investors and traders seeking the latest updates and insights on Paragon 28 stock.

Paragon 28 Inc (FNA) is a leading innovator in foot and ankle orthopedic devices, specializing in surgical solutions that enhance patient outcomes. This news hub provides investors and healthcare professionals with essential updates on the company’s financial performance, product developments, and industry leadership.

Access real-time announcements including quarterly earnings reports, FDA-cleared device launches, and strategic partnerships with surgical institutions. Our curated collection features regulatory milestones, clinical trial results, and executive commentary – all critical for understanding FNA’s position in the $5B+ global foot and ankle device market.

Key updates cover innovative implant systems, surgeon training initiatives, and manufacturing expansions that demonstrate Paragon 28’s commitment to advancing orthopedic care. Bookmark this page for verified updates on procedural innovations like fracture fixation solutions and deformity correction technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.2%
Tags
conferences earnings
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.76%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.32%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
-
Rhea-AI Summary

Paragon 28, Inc. (NYSE: FNA), a leading medical device company focused on foot and ankle orthopedics, will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on May 10, 2023, at 5:20 p.m. ET. The event will feature Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO. Investors can access a live webcast and the archived recording via the company's investor relations website.

Based in Englewood, Colo., Paragon 28 aims to improve patient lives with innovative orthopedic solutions addressing various foot and ankle conditions. The company's offerings focus on enhancing surgical outcomes and reducing complication rates, reflecting their commitment to patient and surgeon needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences
Rhea-AI Summary

Paragon 28, Inc. (NYSE: FNA) has launched its innovative Phantom® Metatarsal Shortening System, designed for in-line shortening osteotomies of the lesser metatarsals, which treat common foot ailments like metatarsalgia and floating toe. The system features a patent-pending cut guide for enhanced precision. CEO Albert DaCosta emphasized the system's potential to drive growth in the forefoot segment, complementing the company's existing portfolio, including TenoTac™ and HammerTube™. The launch aims to provide a comprehensive solution for surgeons addressing forefoot conditions.

Contributors to the design include renowned surgeons, underscoring the system's innovative approach to improving patient outcomes in foot and ankle orthopedic procedures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none

FAQ

What is the current stock price of Paragon 28 (FNA)?

The current stock price of Paragon 28 (FNA) is $13.1 as of April 29, 2025.

What is the market cap of Paragon 28 (FNA)?

The market cap of Paragon 28 (FNA) is approximately 1.1B.
Paragon 28 Inc

NYSE:FNA

FNA Rankings

FNA Stock Data

1.09B
56.99M
31.77%
52.42%
1.72%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
ENGLEWOOD